Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer

BACKGROUND: Switching patients who remain at high risk of skeletal related events (SREs) despite pamidronate to the more potent bisphosphonate zoledronate, may be an effective treatment strategy. As part of a previously reported clinic study in this setting, we evaluated whether biomarkers for bone...

Full description

Saved in:
Bibliographic Details
Published in:J Bone Oncol
Main Authors: Hilton, J.F., Clemons, M., Pond, G., Zhao, H., Mazzarello, S., Vandermeer, L., Addison, C.L.
Format: Artigo
Language:Inglês
Published: Elsevier 2017
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5709351/
https://ncbi.nlm.nih.gov/pubmed/29204337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2017.11.001
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items